21,268 Shares in Dermira Inc (NASDAQ:DERM) Purchased by GYL Financial Synergies LLC

GYL Financial Synergies LLC bought a new position in Dermira Inc (NASDAQ:DERM) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm bought 21,268 shares of the biopharmaceutical company’s stock, valued at approximately $288,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. BNP Paribas Arbitrage SA increased its stake in shares of Dermira by 48,273.3% during the first quarter. BNP Paribas Arbitrage SA now owns 7,256 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 7,241 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Dermira by 2,500.0% during the first quarter. Nisa Investment Advisors LLC now owns 10,400 shares of the biopharmaceutical company’s stock worth $141,000 after acquiring an additional 10,000 shares during the period. Metropolitan Life Insurance Co. NY increased its stake in shares of Dermira by 356.7% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 12,912 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 10,085 shares during the period. Nomura Holdings Inc. grew its position in Dermira by 18.5% during the fourth quarter. Nomura Holdings Inc. now owns 75,696 shares of the biopharmaceutical company’s stock worth $544,000 after buying an additional 11,836 shares during the period. Finally, Geode Capital Management LLC grew its position in Dermira by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 392,484 shares of the biopharmaceutical company’s stock worth $2,821,000 after buying an additional 12,060 shares during the period. 93.92% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have weighed in on the stock. HC Wainwright set a $31.00 target price on shares of Kura Oncology and gave the stock a “buy” rating in a research report on Wednesday, May 8th. ValuEngine raised shares of ZEALAND PHARMA/S from a “sell” rating to a “hold” rating in a report on Friday, March 15th. Mizuho initiated coverage on shares of Sabre in a research note on Thursday, June 6th. They set a “buy” rating and a $25.00 price objective on the stock. BidaskClub raised shares of DENTSPLY SIRONA from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 13th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $8.00 price target on shares of Pacific Biosciences of California in a research note on Friday, May 3rd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $17.97.

NASDAQ DERM traded down $0.05 during trading hours on Friday, reaching $8.76. 590,460 shares of the company traded hands, compared to its average volume of 700,783. Dermira Inc has a 12 month low of $6.00 and a 12 month high of $15.48. The company has a quick ratio of 6.92, a current ratio of 7.13 and a debt-to-equity ratio of 4.36. The stock has a market capitalization of $472.81 million, a PE ratio of -1.67 and a beta of 1.34. The stock has a 50 day simple moving average of $9.50.

Dermira (NASDAQ:DERM) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.49) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.10) by ($0.39). The business had revenue of $2.45 million during the quarter, compared to the consensus estimate of $2.63 million. Dermira had a negative return on equity of 391.86% and a negative net margin of 510.47%. Analysts forecast that Dermira Inc will post -5.2 EPS for the current year.

Dermira Profile

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Recommended Story: Capital Gains Distribution

Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.